目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T8668 | HSP | ||
HM03 是一种有效的选择性 HSPA5 抑制剂,具有抗癌活性。 | |||
T9963 | HDAC | ||
MPT0B390 是 HDAC 抑制剂和 TIMP3 诱导剂,可抑制肿瘤生长、转移和血管生成。 | |||
T9696 | Wnt/beta-catenin | ||
β-catenin-IN-2 是有效的β-catenin 抑制剂。β-catenin-IN-2在结直肠癌中有研究的价值。 | |||
T9810 | Wnt/beta-catenin | ||
TNIK-IN-5 是高效的 TNIK 抑制剂 (IC50= 0.05 μM)。TNIK-IN-5 可以有效抑制细胞中的 Wnt 信号通路。TNIK-IN-5 在体外显示出良好的抗结直肠癌活性。 | |||
T8500 | OXPHOS Mitochondrial Metabolism Autophagy | ||
VLX600 是一种铁螯合氧化磷酸化抑制剂,是一种细胞渗透性抗癌剂。它通过减少肿瘤细胞中的线粒体氧化磷酸化起作用。 | |||
T11898 | Raf | ||
LXH254 是B/C RAF 抑制剂。 | |||
T6759 | Glucokinase | ||
AP-III-a4 (ENOblock) 是第一个非底物类似物,可直接与烯醇酶结合,IC50=0.576 uM,可阻碍体内癌细胞转移。 | |||
T8973 | Others | ||
HS-1793 是 resveratrol 类似物,可以诱导细胞凋亡,在多种癌细胞中有抗肿瘤的能力。 | |||
T6255 | Epigenetic Reader Domain CDK | ||
Bromosporine 是广谱 BRD2/4/9 和 CECR2 溴结构域抑制剂,IC50为0.41、0.29、0.122和0.017 μM。 | |||
T2099 | Mitophagy BCL Autophagy | ||
ABT737 是 BH3 模拟物,是Bcl-2、Bcl-xL 和Bcl-w 抑制剂,EC50分别为 30.3 nM、78.7 nM 和 197.8 nM。它诱导自噬,有研究急性髓系白血病的潜力。它还诱导 BCL-2/BAX 复合物的破坏和 BAK 依赖性。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04023 | BCCIP Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The secondary genetic alternations may overcome the progression suppression imposed by BCCIP deficiency through a synthetic viability mechanism. Knockdown of YY1 inhibited the binding of BCCIP itself at BCCIP promoter region proximal to TSS, demonstrating that transcriptional regulation of the YY1 on BCCIP can be modulated by BCCIP itself in a YY1-dependent fashion. BCCIP (BRCA2 and CDKN1A interacting protein) plays a critical role in maintaining the critical functions of p53 in tumor suppression and response to therapy. Celecoxib affects the functions of p53 and inhibits the recovery from the irradiation-induced injury by up-regulating the expression of BCCIP, and subsequently regulates the expressions of genes such as p21 and Cyclin B1 to enhance the radiosensitivity of HCT116 cells in a COX-2 independent manner.
|
|||||
TMPY-00578 | BCCIP Protein, Human, Recombinant | Human | Baculovirus-Insect Cells | ||
BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The secondary genetic alternations may overcome the progression suppression imposed by BCCIP deficiency through a synthetic viability mechanism. Knockdown of YY1 inhibited the binding of BCCIP itself at BCCIP promoter region proximal to TSS, demonstrating that transcriptional regulation of the YY1 on BCCIP can be modulated by BCCIP itself in a YY1-dependent fashion. BCCIP (BRCA2 and CDKN1A interacting protein) plays a critical role in maintaining the critical functions of p53 in tumor suppression and response to therapy. Celecoxib affects the functions of p53 and inhibits the recovery from the irradiation-induced injury by up-regulating the expression of BCCIP, and subsequently regulates the expressions of genes such as p21 and Cyclin B1 to enhance the radiosensitivity of HCT116 cells in a COX-2 independent manner.
|